Sylvan Baca MD PhD (Hiring!)
135 posts
@SylvanBacaLab
GU oncologist and computational epigenomics enthusiast at @DanaFarber, Assistant Professor @harvardmed
Nucleosome aficionados! Our new review "Nucleosome spacing across cell types, diseases, and ages" is out in NAR: academic.oup.com/nar/article/54… A huge effort to pull together what we’ve learned about nucleosome spacing in many systems. Enjoy! #nucleosomics #nucleosome #chromatin #cfDNA
Amazing work out of @SylvanBacaLab by our very own raising star @RashadNawfal Plasma cfChIP-seq (H3K4me3) predicted DLL3 expression in NEPC. Higher promoter signal in NEPC tumors distinguishing DLL3+ vs DLL3– Potential blood-based approach to guide DLL3-targeted therapy selection. #GU26 #ProstateCancer #NEPC @OncoAlert
We infer earthquakes from distant vibrations and stars from photons emitted light-years away. Can we reconstruct a patient’s tumor biology from the signals it sheds into blood? Introducing APEX (Associating Plasma Epigenomics with eXpression), our framework for inferring cancer expression from plasma. Preprint: biorxiv.org/content/10.648… @biorxivpreprint @DanaFarber @DrChoueiri @SylvanBacaLab #FreedmanLab
Very excited our paper is online! @adib_elio @WinstonCheung5 @SylvanBacaLab @DrChoueiri #MattFreedman. sciencedirect.com/science/articl… We profile chromatin and transcription across normal kidney →primary ccRCC→metastasis to define what changes (and what persists) during progression 1/
Our latest paper is now out in @jclinicalinvest! 🎉Huge congrats to superstars🌟 @simongarinet & @karlsemaan on this study with @sylvanbacalab #FreedmanLab @drchoueiri. [1]
Are liquid biopsy tools that capture gene expression the future of precision oncology? We tackle this question and share our vision for Precision Oncology 2.0 in @JCO_ASCO: ascopubs.org/doi/10.1200/JC… with @DrChoueiri , #MattFreedman, @SylvanBacaLab at @DanaFarber .
JUST IN: Congrats to our own @gungulati @SylvanBacaLab #Mattfreedman @DanaFarber + @DanaFarber_GU New commentary published in @JCO_ASCO @ASCO : From mutations to expression=> Precision Oncology 2.0 reveals that expression-based liquid biopsy can guide therapy selection, switching and resistance monitoring Exciting for 2026 and beyond! ascopubs.org/doi/pdf/10.120…
Burcu Darst, Sylvan Baca, Jeremie Calais, and @RaqPerezLopez will discuss "Recent Advances in Risk, Detection, and Diagnosis" in a plenary at the AACR Conference on Prostate Cancer (January 20-22; Boston). brnw.ch/21wXDxt #AACRprostate26 @SylvanBacaLab @CalaisJeremie
